ProfileGDS5678 / 1432347_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 44% 44% 44% 46% 44% 51% 43% 44% 44% 41% 44% 45% 44% 44% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 13.0756344
GSM967853U87-EV human glioblastoma xenograft - Control 23.0331444
GSM967854U87-EV human glioblastoma xenograft - Control 33.0347244
GSM967855U87-EV human glioblastoma xenograft - Control 43.0134646
GSM967856U87-EV human glioblastoma xenograft - Control 52.9728644
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 13.3225351
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 23.0741843
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 33.0073144
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 43.0134444
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 12.940841
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 23.0153244
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 33.0029645
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 43.0292644
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 53.0247344